Celgene discontinues Phase I of anti-CD47 antibody in AML/MDS

Celgene Corp. (NASDAQ:CELG) discontinued a Phase I trial evaluating CC-90002 (INBRX-103) to treat acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). According to ClinicalTrials.gov, the company terminated the trial because preliminary data "did not offer a sufficiently encouraging profile for further dose escalation/expansion."

Celgene did not respond to inquiries regarding details or next steps for the anti-CD47 antibody. The open-label, dose-escalation, U.S. trial enrolled 28 patients to receive IV CC-90002...